Biomarkers in Cardiovascular Disease—Chances and Risks

Dear Colleagues,

I cordially invite you to submit your valuable work covering a very interesting topic: “Biomarkers in Cardiovascular Disease—Chances and Risks”, a rapidly evolving field in recent years.

A proper diagnosis of many cardiac diseases such as myocardial infarction, heart failure, and inborn defects of metabolism relies on the adequate use of biomarkers. In some situations, the information received can be decisive for treatment. In others, together with the results of other investigations, the use of biomarkers can accelerate proper diagnosis and treatment.

There is a growing role of multiple biomarkers in the risk models for prognosis in cardiovascular diseases—their use in prognostic models or in the validation of biomarker-based models are welcome as part of this topic.

Another fascinating and rapidly growing field is the use of Artificial Intelligence prognostic.

Despite the long history of biomarkers in cardiovascular medicine, there are still many unsolved questions about the reproducibility, measurement accuracy, influence of external factors, and the true sensitivity, specificity, and biological significance of those tests—herein, I see a clear limitation to and risk of wide biomarker use.

Every biomarker should be extensively tested before its clinical acceptance and wider use in clinical settings—I hope that your work will contribute enormously to the quest for the ideal biomarker in cardiovascular diseases.

I look forward to see your scientific contribution to this fascinating field.

Prof. Dr. Tomasz Zieliński
Dr. Anna Konopka
Topic Editors